CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Corona Virus (COVID-19) Impact on CHEPLAPHARM activities

Dear Customer,

Due to the COVID-19 Situation, CHEPLAPHARM Arzneimittel GmbH is closely monitoring the potential impact on the various Supply Chalns and is committed to keep a transparent approach to all involved Partners, Customers and Authorities.

We have prepared in this regards a list of the most common questions and answers associated to COVID-19, please see below:

1/ ls CHEPLAPHARM directly impacted by COVID-19?

No, we are not impacted. CHEPLAPHARM has implemented preventive actions to minimize the risk of business impact, e.g. health protection of our employees.

2/ ls CHEPLAPHARM or a supplier of CHEPLAPHARM manufacturing in Wuhan City or the Hubei province?

No, we do not have any active suppliers or partners producing in this province.

3/ ls CHEPLAPHARM or a supplier of CHEPLAPHARM manufacturing in ltaly, France or Spain?

Yes, we do have suppliers or partners producing in these countries. Currently our suppliers are running their production with slightly reduced capacities. This is the result of a reduced number of employees. Our suppliers in Italy are officially classified by the government as "Pharma & Food" and therefore not affected by plant closures.

4/ Are any other locations worldwide affected by restricted related to COVID-19?

We remain in dose contact with all our suppliers and receive weekly status reports in this regard. Currently our suppliers, e.g. in Spain or France, are monitoring the Situation in Italy very closely and establishing appropriate precautionary measures very early on.

5/ Does CHEPLAPHARM have a warehouse in China or other affected regions?

We do not have a warehouse in China or outside Germany.

6/ ls CHEPLAPHARM already experiencing delivery issues for the above reasons?

We do not have currently negative impact due to COVID-19 on the Supply Chain. We closely monitor the situation at a weekly basis.

7/ Does CHEPLAPHARM see risks from current or planned border closures within the European Union?

At present, we are seeing longer lead-times for shipments to Germany and other EU countries. Transport capacities are also generally reduced and freight costs are rising. The "Green Lanes" that have been set up in the meantime have been able to significantly reduce waiting times for medical devices.

Airfreight: There are also shifts or cancellations for planned routes. Our logistics department is in daily contact with our partners and is informed about current capacities and alternative routes.

8/ Which measures has CHEPLAPHARM taken in order to avoid getting into the above-mentioned difficulties?

Our business continuity teams meet weekly from all the regions to review imports and exports from impacted areas and if necessary prioritize shipments. We hold safety stocks for all active ingredients and finished pharmaceutical goods in order to cope with short-term delivery shortcomings.

Would the situation evolve, we would naturally review and update this list.

CHEPLAPHARM remains reachable for any complement of information.

Kind regards

CHEPLAPHARM Arzneimittel GmbH

Mathias Natschke

Director Supply Chain Management


Investor Relations topics

Back to top expand_less